Immuron (ASX:IMC) — Material Events
ASX:IMC · 11 articles in the last 12 months · 100% assessed
Click a band to jump to that tier
Major ≥90
Significant 75–89
Notable 50–74
Routine <50
Not assessed
Immuron Advances Oral Therapy IMM-529 for C. difficile with FDA IND FilingMedium
Immuron submits IND for IMM-529 to treat and prevent C. difficile infection, plans Phase 2 trial in 2026
8 Oct 2025
·Regulatory Filing
·85
Immuron’s IMM-529 Gains FDA Nod, Phase 2 Trial Set to Tackle C. diffMedium
Immuron’s IMM-529 IND Approved by FDA, Phase 2 Trial to Commence for CDI Treatment
5 Nov 2025
·Regulatory Approval Announcement
·85
Immuron Advances with FDA Nod and Record Sales Despite Ongoing LossesMedium
Immuron reports reduced half-year loss, FDA IND approval for IMM-529, and strong sales growth
25 Feb 2026
·Half-Year Report
·85
Immuron Posts 16% Q3 Sales Growth on Travelan Expansion Amid Currency HeadwindsMedium
Immuron Reports Double-Digit Q3 Sales Growth Driven by Travelan®
17 Apr 2026
·Sales Update
·75
Immuron’s Travelan Sales Surge 34% in Q1 FY26 Led by Australia and USMedium
Immuron Q1 FY26 sales up 34% driven by Australia and USA growth
13 Oct 2025
·Sales Update
·75
Immuron Navigates FDA Review Amid Travelan® Trial DelayMedium
Immuron Updates on IMM-529 FDA Review and Travelan® Clinical Trial Delay
31 Oct 2025
·Clinical Trial Update
·75
Immuron Posts 6% FY26 Sales Rise Led by Canada and US GrowthMedium
Immuron FY26 Sales Up 6% with Strong Growth in Canada and US
16 July 2026
·Sales Update and Corporate Presentation
·75
Immuron Unveils PROIBS® to Tackle IBS Symptoms Ahead of Festive SeasonMedium
Immuron launches PROIBS® for IBS treatment in Australia with strong initial demand
24 Oct 2025
·Product Launch Announcement
·75
Immuron Reports 6% Revenue Growth and FDA Nod Amid Strategic ResetMedium
Immuron FY26 results show revenue growth, improved net loss, FDA approval, and strategic reset for profitability
28 Aug 2026
·Preliminary Financial Results
·70
Immuron Clarifies Trial Setback, Eyes FDA with Proven Travelan DosingMedium
Immuron reports non-significant trial results for third-party ETEC product; to propose established Travelan dosing to FDA
10 Dec 2025
·Clinical Trial Update
·70
Immuron Denies Undisclosed Info Amid Share Price Surge, Cites CEO ConferenceMedium
Immuron Limited denies undisclosed info amid share price surge, cites CEO conference presentation
28 May 2026
·Price Query Response
·60
No articles in this tier for the last 12 months.
Market Mentions
5
- appeared in market wrap coverage
These are market wrap articles where Immuron (ASX:IMC) was mentioned. They reflect broader market coverage, not company-specific announcements.
Healthcare Wrap - Week 35 (24 Aug -> 28 Aug) 2026
29 Aug 2026
Healthcare Wrap - Week 29 (13 July -> 17 July) 2026
18 July 2026
Healthcare Wrap - Week 22 (25 May -> 29 May) 2026
30 May 2026
Healthcare Wrap - Week 16 (13 Apr -> 17 Apr) 2026
18 Apr 2026
Healthcare Wrap - Week 9 (23 Feb -> 27 Feb) 2026
28 Feb 2026